Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 7:10 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 5,056 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Capsule 2 Clear all

Conditions: Atrial Fibrillation or Flutter
Interventions: Vanoxerine HCl, Placebo; Drug
Lead sponsor: Laguna Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 4
States / cities: Littleton, Colorado • Washington D.C., District of Columbia • Iowa City, Iowa + 1 more

Conditions: Antibiotic Enterocolitis
Interventions: Amoxicillin Oral Capsule; Drug
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Colonic Cancer
Interventions: Aquamin®, Calcium Carbonate, Placebo; Drug
Lead sponsor: James Varani; Other
Eligibility: 18 Years to 80 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Cognitive Impairment Associated With Schizophrenia (CIAS)
Interventions: PF-04958242, placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 16
States / cities: Garden Grove, California • Oceanside, California • Orange, California + 11 more

Conditions: Glioblastoma
Interventions: BKM120 + temozolomide, BKM120 +temozolomide with/without radiotherapy; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 3
States / cities: Fayetteville, Arkansas • Boston, Massachusetts • Houston, Texas

Conditions: Advanced Cancer
Interventions: Valproic Acid, Bevacizumab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: COVID-19, Coronavirus, SARS-CoV2 Infection
Interventions: Rayaldee, Placebo; Drug
Lead sponsor: OPKO Health, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 10
States / cities: San Francisco, California • Miami, Florida • Evanston, Illinois + 6 more

Conditions: KRAS Mutation-Related Tumors, Metastatic Solid Tumor, Advanced Solid Tumor
Interventions: TPX-0005, Trametinib; Drug
Lead sponsor: Turning Point Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 6
States / cities: California City, California • Denver, Colorado • Nashville, Tennessee + 2 more

Conditions: Bipolar Depression
Interventions: PF-04455242, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Fecal Incontinence
Interventions: Loperamide, Placebo, Anal exercises with biofeedback, Usual Care; Drug · Behavioral
Lead sponsor: NICHD Pelvic Floor Disorders Network; Network
Eligibility: 18 Years and older · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 9
States / cities: Birmingham, Alabama • La Jolla, California • San Diego, California + 6 more

Conditions: Angina Pectoris
Interventions: T89; Drug
Lead sponsor: Tasly Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 15
States / cities: Tucson, Arizona • Beverly Hills, California • Corona, California + 11 more

Conditions: Frail Elderly Syndrome
Interventions: Fisetin, Placebo oral capsule; Dietary Supplement · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 70 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath
Interventions: Pimicotinib(ABSK021), Placebo; Drug
Lead sponsor: Abbisko Therapeutics Co, Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 8
States / cities: Beverly Hills, California • Durham, California • Detroit, Michigan + 5 more

Conditions: Amyotrophic Lateral Sclerosis, Healthy Volunteer
Interventions: SAR443820, Erythromycin ethyl succinate, Itraconazole; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Recreational Drug Use
Interventions: PF614, Oxycodone Hydrochloride 40 mg, Placebo; Drug
Lead sponsor: Ensysce Biosciences; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy Participants
Interventions: H3B-6527; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Progeria, Hutchinson-Gilford Syndrome
Interventions: Lonafarnib; Drug
Lead sponsor: Monica E. Kleinman; Other
Eligibility: 1 Year and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Irritable Bowel Syndrome
Interventions: 250 mg capsule, 250 mg tablets; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Type 2 Diabetes Mellitus
Interventions: Pioglitazone, Placebo, Pancreatic Clamp Study; Drug · Procedure
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2011
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Inflammation
Interventions: Omega-3 fatty acid, Placebo; Dietary Supplement
Lead sponsor: University of Memphis; Other
Eligibility: 60 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Non-small Cell Lung Cancer
Interventions: Sutetinib Maleate Capsule; Drug
Lead sponsor: Teligene US; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 10
States / cities: Glendale, California • La Jolla, California • Tampa, Florida + 7 more

Conditions: Colorectal Cancer Screening
Interventions: PillCam® COLON 2 procedure-CONTROL, Senna tablets, PEG, Metoclopramide, Erythromycin, SUPREP oral sulfate solution, Bisacodyl, SUPREP oral sulfate solution with Gastrografin; Device · Drug
Lead sponsor: Medtronic - MITG; Industry
Eligibility: 50 Years to 75 Years
Enrollment: 122 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 6
States / cities: Anniston, Alabama • Indianapolis, Indiana • Dayton, Ohio + 2 more

Conditions: Chronic Kidney Disease, Type 2 Diabetes Mellitus
Interventions: AZD1722, Placebo; Drug
Lead sponsor: Ardelyx; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Asthma
Interventions: Ginger Extract, Placebo; Drug
Lead sponsor: Emily DiMango, MD; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Safety and Efficacy of Vanoxerine for the Conversion of Subjects With Recent Onset Atrial Fibrillation or Flutter to Normal Sinus Rhythm

Effect of Antibiotics on Enteric Neurons and Glia

Aquamin and Prevention of Colon Cancer

A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)

A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma

Valproic Acid and Bevacizumab in Patients With Advanced Cancer

Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19

A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors

A First In Human Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of PF-04455242 In Single Rising Doses In Healthy Adult Volunteers

Controlling Anal Incontinence by Performing Anal Exercises With Biofeedback or Loperamide (CAPABLe)

Phase II Multi-Center Study of T89 to Treat Chronic Stable Angina

Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Women

Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)

A Study to Assess the Effect of Erythromycin on the Test Medicine (SAR443820) When Given Orally as Tablets to Healthy Adult Male and Female Participants (Part A); and the Effect of Itraconazole on the Test Medicine (SAR443820) When Given Orally as Capsules to Healthy Adult Male Participants (Part B)

A Study to Evaluate the Oral Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users (PF614-104)

A Study to Evaluate the Food-Effect of H3B-6527

Phase II Trial of Lonafarnib (a Farnesyltransferase Inhibitor) for Progeria

An Open-Label Study of Two Formulations of LX1033 in Healthy Human Subjects

The Role of Acute Combined PPAR Alpha and Gamma Stimulation on Insulin Action in Humans

Omega-3 Fatty Acid Supplementation in Older Adults

A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC

Optimization of the Bowel Preparation Regimen for the PillCam® COLON 2 Capsule Endoscopy Procedure

A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria

Ginger's Therapeutic Potential in Asthma